Disturbances in both the genomic locus and expression levels of GPC5 have been reported across a spectrum of human cancers, such as breast cancer (Kiely et al., 2021), lymphoma (Yu et al., 2003), rhabdomyosarcoma (Chui et al., 2018), glioma (Müller et al., 2023), prostate cancer (de Moraes et al., 2021) and pancreatic cancer (Liu et al., 2020). The gene discussed is GPC5; the disease is cancer.